Aurinia Pharmaceuticals Inc.
Income Statement
| Line Item | FY2017 | FY2016 |
|---|---|---|
| Revenue | $418.0K | $173.0K |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | — | — |
| SG&A Expense | — | — |
| Operating Income | $-46.9M | $-25.0M |
| Operating Margin | -11,212.4% | -14,466.5% |
| Interest Expense | — | — |
| Pretax Income | $-70.8M | — |
| Income Tax Expense | $0 | $0 |
| Net Income | $-70.8M | $-23.3M |
| Net Margin | -16,935.9% | -13,465.3% |
| EPS (Basic) | — | — |
| EPS (Diluted) | — | — |
| Shares Outstanding (Basic) | 84.1M | — |
| Shares Outstanding (Diluted) | 84.1M | — |
| Dividends Per Share | — | — |